Status: Recruiting
OM336 in Seropositive Autoimmune Diseases
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Participants needed: 39
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Ouro MedicinesUpdated: Jun 15, 2026Locations: 1
Eligibility criteria
Diagnosis of active seropositive autoimmune disease [+3]
Previous treatment with a BCMA-targeted therapy [+3]